About VYEPTI CONNECT

VYEPTI CONNECT is an optional program that offers support throughout the patient journey—from benefits investigations through appeals—as well as information about possible financial assistance that may be available for eligible patients.

You can enroll your patients in VYEPTI CONNECT by:

Fax icon

Faxing an enrollment form to
866-868-7071

Call icon

Calling 833-4-VYEPTI

Mail icon

Mailing an enrollment form to:
PO Box 29299
Phoenix, AZ 85038-9299

Your VYEPTI CONNECT team is here to answer your access and reimbursement questions

Access and reimbursement support is provided by a team of reimbursement specialists.

VYEPTI CONNECT Liaison

VYEPTI CONNECT Liaisons

When you enroll in VYEPTI CONNECT, you are assigned a liaison to assist with the VYEPTI CONNECT offerings.* Liaisons can be contacted by phone at 833-4-VYEPTI, Monday through Friday, 8 am-8 pm EST.

Field Reimbursement Specialists

Access questions can also be directed to a VYEPTI CONNECT Field Reimbursement Specialist who can help in person or by phone.

Field Reimbursement Specialist

Connecting patients and providers with access support

VYEPTI CONNECT offerings are available for enrolled patients.

*VYEPTI CONNECT resources are only available to patients with a valid prescription for VYEPTI. Click here for full Terms and Conditions for VYEPTI CONNECT.

Benefits Investigation icon

Benefits investigation

VYEPTI CONNECT can gather medical coverage requirements, assignment of benefits, and if applicable, site-of-care requirements of the payer. For assignment of benefits, if Lundbeck’s approved specialty pharmacies are not in the payer’s network, VYEPTI CONNECT can inquire about the letter of agreement process.

Prior Authorization (PA)/Medical Exception icon

Prior authorization (PA) / medical exception

VYEPTI CONNECT can provide information on determining coverage and completing a PA form. Once a PA is submitted, VYEPTI CONNECT can monitor and communicate the status of the PA to the office.

Appeals support icon

Appeals support

VYEPTI CONNECT can provide appeals support by offering information on health plan coverage denials and responses. In addition, VYEPTI CONNECT can monitor and communicate the status of appeals to the office.

Financial assistance icon

Financial assistance

Financial assistance is available for eligible commercially insured patients through the VYEPTI Copay Assistance Program. Patients may pay as little as $5 per infusion every 3 months for VYEPTI. A maximum annual benefit limit of $4000 and other restrictions may apply. Patients can check eligibility requirements and enroll in the program by calling 833-4-VYEPTI, #3, or learn more here.

Resources PDF icon

Access and support resources

Sample letters of medical necessity and appeal, a prior authorization checklist, VYEPTI Copay Assistance Program information, and more tools and downloads are at your fingertips.

†Patients are not eligible for financial assistance if they are uninsured or if their prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare programs, including but not limited to Medicare or Medicaid, United States Department of Veterans Administration, US Department of Defense, or TRICARE. The VYEPTI Copay Assistance Program covers the cost of VYEPTI only. Administration and other fees are not covered by this copay program. Patients must be US residents age 17 years or older and have a valid VYEPTI prescription. Click here for full Terms and Conditions for the VYEPTI Copay Assistance Program.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.